Return to Today's science sparks archives
Click the tweet icon above each article title to share it on Twitter.
|
Fig. 1A 17-year-old boy with cough and posttussive emesis.
|
|
|
Fig. 1 Chemical structure of FDG-mNP and disruption of cancer cell.
|
 |
|
Fig. 1 An individual’s unique mutational signature is a record of the types of DNA alterations sustained throughout their lifetime and can be studied to identify unique patterns of etiology-specific alterations, including carcinogens or DNA repair pathway defects, the latter of which can be inherited or acquired during oncogenesis.
|
|
|
Fig. 2 Structure of apalutamide.
|
|
|
Fig. 1 Tpo-Cre/FR-HrasG12V+/+/p53f/f mice develop anaplastic and poorly differentiated thyroid cancers.
|
|
|
Fig. 1 Treatment fields for whole-brain radiation therapy.
|
|
|
Fig. 3 Unsupervised clustering heat map of genome-wide mRNA expression profiles, using skin samples from 49 MF/SS patients and 3 healthy individuals.
|
|
|
Fig. 1 Generation of mono-hormonal pancreatic β-like cells through the induction of late-stage pancreatic progenitors (PP2).
|
|
|
Fig. 1 Cohort 1: Oncology patients who were receiving active treatment and presented to urgent care with a Centers for Medicare & Medicaid Services–defined potentially preventable symptom (6,429 urgent care visits).
|
|
|
Fig. 1 Flow diagram describing the main components of computational radiomics pipeline in Computational Environment for Radiological Research (CERR).
|
|
|
Fig. 1 Neuroendocrine neoplasm of the ear showing solid and nested pattern with glandular structures.
|
|
|
Fig. 1 Likelihood of using a list of best hospitals for cancer surgery and information patients would have wanted to know about hospitals.
|
|
|
Fig. 1 Loss of miR-146a in B cells led to spontaneous GC reactions in aged mice.
|
|
|
Fig. 2 The impact of changing diagnostic thresholds on screening related overdiagnosis.
|
|
|
Fig. 1 MASTL expression is upregulated in colon cancer. Patients were evaluated by tumor stage and expression levels were compared to expression levels of normal adjacent samples.
|
|
|
Fig. 2 Computational pipeline used to derive a set of marker genes, the NET Marker Panel that identifies GEP-NEN/NET disease in the blood.
|
|
|
Fig. 4 A 41-year-old woman with a positive family history.
|
|
|
Fig. 2 Time to Composite Primary End Point by Type of Results Reported
|
|
|
Fig. 2 Live cell imaging of rucaparib uptake.
|
|
|
Fig. 3 CT scans showing confirmed partial response in one patient (250 mg BID).
|
|
|
Fig. 1 Sacral chordoma involving most of the sacrum (yellow arrow).
|
|
|
Fig. 1 Chemical structures of all compounds included in this study.
|
|
|
Fig. 1 Targeted mutational burden (TMB) by age.
|
|
|
Fig. 3 Pyruvate metabolism in a small ovarian cancer metastasis (Patient 4) after systemic chemotherapy.
|
|
|
Fig. 1 Best overall response (A), progression-free survival (PFS) (B), and overall survival (OS) (C) in patients with RCC treated with ICI, stratified by use of ATB within 30 days of initiating ICI.
|
|
|
Fig. 1 Hedgehog Signaling Pathway.
|
|
|
Fig. 2 Atrx deficiency modulates mNPC differentiation state.
|
|
|
Fig. 2 Biophysical and biochemical properties of free lysine (Lys) and methyllysine (Kme1/2/3).
|
|
|
Fig. 3 Cell-nonautonomous compensation by spared neighbours in response to mosaic blockade of chondrocyte proliferation.
|
|
|
Fig. 6 Integrative omics analysis of druggability.
|
|
|
Fig. 1 Venn diagram of fatigue, pain severity and insomnia.
|
|
|
Fig. 1 Adaptive biomarker trial design.
|
|
|
Fig. 1 Greater 18F-fluciclovine avidity than 18F-FDG avidity in a patient with a right breast ILC.
|
|
|
Figure 4. Repeat Element Expression Is a Predictor of Colon Tumor Immune Infiltration and Patient Survival.
|
|
|
Fig. 1 Stimulation of BV-2 cells with rHIgM22 promotes myelin phagocytosis.
|
|
|
Fig. 2 Force types and force screen.
|
|
|
Fig. 1 Copy number loss of KDM5D in PC.
|
|
|
Fig. 1 Plane of capsular dissection (dotted line) during thyroidectomy, dividing vasculature medial (distal) to the parathyroid glands in order to allow preservation of the parathyroid blood supply.
|
|
|
Fig. 1 Fanconi triple assessment: patients being evaluated for FA require a triple assessment, including (A) history/physical examination, (B) clastogenic testing or chromosomal breakage testing with diepoxybutane ± mitomycin C, and (C) genetic testing.
|
|
|
Fig. 1 Antibody-mediated detection of PGRN in tissue or cells by IHC and IF.
|
|
|
Fig. 1 Chimeric Antigen Receptor (CAR) T Cells Engrafting, Trafficking to Tumor, and Proliferating Extensively after Infusion.
|
|
|
Fig. 2 Cox-2 immunohistochemical staining. Figure contains immunohistochemical staining for Cox-2 showed a wide spectrum of cytoplasmic reactivity ranging from no staining (A), weak staining (B), to diffuse strong staining (C) in the lesional adenoma cells.
|
|
|
Fig 1. Molecular classes of acute myeloid leukemia (AML) and recurrent gene mutations shows the complexity of the genetics of AML.
|
|
|
Fig. 2.1 DSB repair pathways. The two major DSB repair pathways in mammalian cells are nonhomologous end-joining (NHEJ) and homologous recombination (HR).
|
|
|
Fig. 1 Thirteen combinations of dose-toxicity and dose-efficacy curves from Yin et al.
|
|
|
Fig. 1 Potential reasons for cancer patients' increased risk of ischemic stroke. The diagram depicts the possible underlying explanations for cancer patients' heightened stroke risk.
|
|
|
Fig. 1 Somatic genetic alterations identified in 17 ER-negative/HER2-positive and triple-negative breast tumors and matched brain or skin metastases by massively parallel sequencing of 341 cancer-related genes.
|
|
|
Fig. 1 Table. Assessment of Code From 16 Published Articles.
|
|
|
Fig. 1 Pooled CRISPR screening strategies. In a pooled CRISPR screen, a lentiviral sgRNA library is transduced into a cell population at a low multiplicity of infection (MOI) with the goal that each cell receives only one sgRNA integration.
|
|
|
Fig. 1 Quantitative imaging workflow for prediction of tumour response.
|
|
|
Fig 2. Time to response and durability of response from the start of therapy in complete responders who discontinued pembrolizumab and proceeded to observation (n = 67). Bar length is equivalent to the time to the last imaging assessment by investigator review. CR, complete response; PD, progressive disease; PR, partial response.
|
|
|
FIGURE 1. Delayed PET/CT-guided biopsy of bone metastasis from prostate carcinoma in 64-
y-old man with strongly suspected metastatic prostate carcinoma (prostatic-specific antigen level, 91 ng/mL), without history of bone radiotherapy.
|
|
|
Fig 4. Electron Densities and Overall Path for RNA
|
|
|
Fig. 1 Development of patient-derived neuroendocrine prostate cancer models.
|
|
|
Fig 2. Genomic alteration clusters annotated by cell of origin and molecular pathway.
|
|
|
Fig 7. ZCCHC8CTD stimulates RNA-dependent ATPase activity of MTR4. Time courses of ATP hydrolysis in the presence or absence of the 3′ A25 tailed RNA duplex.
|
|
|
Fig 3. Measurement of the affinity of zefn-A5ECD for mEphA4LBD and zRETECD.
|
|
|
Figure 2. Cross-Platform Classification Revealed Genomic, Epigenomic, and Transcriptomic Similarities and Differences across Cancer Types.
|
|
|
Fig. 1 Photograph illustrating the different locations of ureteroenteric anastomosis in extracorporeal versus intracorporeal diversion.
|
|
